Last reviewed · How we verify
azacitidine and idarubicin
At a glance
| Generic name | azacitidine and idarubicin |
|---|---|
| Sponsor | Groupe Francophone des Myelodysplasies |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (PHASE3)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies (PHASE1)
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (PHASE2)
- Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients (PHASE3)
- AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- azacitidine and idarubicin CI brief — competitive landscape report
- azacitidine and idarubicin updates RSS · CI watch RSS
- Groupe Francophone des Myelodysplasies portfolio CI